Sixty years ago, Steele, Richardson and Olszewski designated progressive supranuclear palsy (PSP) as a new clinicopathological entity in their seminal paper. Since then, in addition to the classic Richardson’s syndrome (RS), different clinical phenotypic presentations have been linked with this four-repeat tauopathy. The clinical heterogeneity is associated with variability of regional distribution and severity of abnormal tau accumulation and neuronal loss. In PSP subtypes, the presence of certain clinical pointers may be useful for antemortem prediction of the underlying PSP-tau pathology. Midbrain atrophy on conventional MRI correlates with the clinical phenotype of RS but is not predictive of PSP pathology. Cerebrospinal fluid biomarkers and tau ligand positron emission tomography are promising biomarkers of PSP. A multidisciplinary approach to meet the patients’ complex needs is the current core treatment strategy for this devastating disorder.
Citations
Citations to this article as recorded by
PSP-Richardson syndrome mimics: An overview and pragmatic approach J. Necpál, M. Borsek, B. Jeleňová Revue Neurologique.2024; 180(1-2): 12. CrossRef
Mechanisms linking cerebrovascular dysfunction and tauopathy: Adding a layer of epiregulatory complexity Yoon A. Kim, Marian Mellen, Caghan Kizil, Ismael Santa‐Maria British Journal of Pharmacology.2024; 181(6): 879. CrossRef
Concomitant Medications for Progressive Supranuclear Palsy Jay M. Iyer, Douglas Gunzler, Anthony E. Lang, Lawrence I. Golbe, Alexander Pantelyat, Adam L. Boxer, Anne-Marie Wills JAMA Neurology.2024; 81(3): 295. CrossRef
SEND-PD in Parkinsonian Syndromes: Results of a Monocentric Cross-Sectional Study Linda Veith Sanches, Stephan Greten, Johanna Doll-Lee, Sophia Rogozinski, Johanne Heine, Lea Krey, Sarana Ulaganathan, Ida Jensen, Matthias Höllerhage, Sam Sani, Günter Höglinger, Florian Wegner, Martin Klietz Neuropsychiatric Disease and Treatment.2024; Volume 20: 1849. CrossRef
Existing statistical measures and techniques in detecting and evaluating progressive supranuclear palsy, its phenotypes by using MRI modalities: A Review Nirmal Adam Sait, J Kathirvelan Materials Today: Proceedings.2023; 80: 2000. CrossRef
The role of magnetic resonance imaging in the diff erential diagnosis of Parkinson’s disease A. A. Tappakhov, T. E. Popova Russian neurological journal.2023; 28(1): 5. CrossRef
Clinical features of progressive supranuclear palsy Yafei Wen, Qijie Yang, Bin Jiao, Weiwei Zhang, Jingyi Lin, Yuan Zhu, Qian Xu, Hui Zhou, Ling Weng, Xinxin Liao, Yafang Zhou, Junling Wang, Jifeng Guo, Xinxiang Yan, Hong Jiang, Beisha Tang, Lu Shen Frontiers in Aging Neuroscience.2023;[Epub] CrossRef
Midbrain area and the hummingbird sign from brain MRI in progressive supranuclear palsy and idiopathic normal pressure hydrocephalus Johan Virhammar, Harald Blohmé, Dag Nyholm, Charalampos Georgiopoulos, David Fällmar Journal of Neuroimaging.2022; 32(1): 90. CrossRef
Cognitive, Psychiatric, and Motor Symptoms–Based Algorithmic Approach to Differentiate Among Various Types of Dementia Syndromes Rehab Magdy, Mona Hussein Journal of Nervous & Mental Disease.2022; 210(2): 129. CrossRef
Idiopathic normal pressure hydrocephalus-like MRI features in patients with progressive supranuclear palsy: a comparative case-control study Halil Onder, Bilge Kocer, Selcuk Comoglu Neurological Research.2022; 44(9): 807. CrossRef
Targeting alpha-synuclein or tau for treating neurodegenerative movement disorders M. Lopez-Cuina, W.G. Meissner Revue Neurologique.2022; 178(5): 460. CrossRef
Clinical Aspects of the Differential Diagnosis of Parkinson’s Disease and Parkinsonism Hae-Won Shin, Sang-Wook Hong, Young Chul Youn Journal of Clinical Neurology.2022; 18(3): 259. CrossRef
Dopamine transporter imaging in progressive supranuclear palsy: Severe but nonspecific to subtypes Qi‐Si Chen, Xin‐Yi Li, Ling Li, Jia‐Ying Lu, Yi‐Min Sun, Feng‐Tao Liu, Chuan‐Tao Zuo, Jian Wang Acta Neurologica Scandinavica.2022; 146(3): 237. CrossRef
CSF tau microtubule-binding region identifies pathological changes in primary tauopathies Kanta Horie, Nicolas R. Barthélemy, Salvatore Spina, Lawren VandeVrede, Yingxin He, Ross W. Paterson, Brenton A. Wright, Gregory S. Day, Albert A. Davis, Celeste M. Karch, William W. Seeley, Richard J. Perrin, Rama K. Koppisetti, Faris Shaikh, Argentina L Nature Medicine.2022; 28(12): 2547. CrossRef
Role of Multivoxel MR Spectroscopy Progressive Supranuclear Palsy – A Preliminary Study Sandhya Mangalore, Manoj Kumar, Pramod Pal, Jitender Saini, Shaik Pasha, Ravi Yadav Neurology India.2022; 70(6): 2388. CrossRef
Genetics of Progressive Supranuclear Palsy: A Review Yafei Wen, Yafang Zhou, Bin Jiao, Lu Shen Journal of Parkinson's Disease.2021; 11(1): 93. CrossRef
Disease course and treatment patterns in progressive supranuclear palsy: A real-world study John C. Morgan, Xiaolan Ye, Jennifer A. Mellor, Keisha J. Golden, Jorge Zamudio, Louis A. Chiodo, Yanjun Bao, Tao Xie Journal of the Neurological Sciences.2021; 421: 117293. CrossRef
Central nystagmus in progressive supranuclear palsy: A neglected clinical feature? Maja Klarendic, Manja Hribar, Nina Bozanic Urbancic, Nina Zupancic, Milica G. Kramberger, Maja Trost, Saba Battelino, Diego Kaski, Maja Kojovic Parkinsonism & Related Disorders.2021; 84: 15. CrossRef
Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial Günter U Höglinger, Irene Litvan, Nuno Mendonca, Deli Wang, Hui Zheng, Beatrice Rendenbach-Mueller, Hoi-Kei Lon, Ziyi Jin, Nahome Fisseha, Kumar Budur, Michael Gold, Davis Ryman, Hana Florian, Anwar Ahmed, Ikuko Aiba, Alberto Albanese, Kelly Bertram, Yvet The Lancet Neurology.2021; 20(3): 182. CrossRef
A Study on the Essential and Parkinson’s Arm Tremor Classification Vasileios Skaramagkas, George Andrikopoulos, Zinovia Kefalopoulou, Panagiotis Polychronopoulos Signals.2021; 2(2): 201. CrossRef
Progressive Supranuclear Palsy: Improvement in Cognitive-Behavioral Disturbances and Motor-Function Disabilities Following Treatment With Antidepressants and Cholinesterase Inhibitors Michelle Oyeka, Terngu Ibilah, Jacob Israel, Jose Gavito-Higuera, Ricardo Salazar Cureus.2021;[Epub] CrossRef
Progressive supranuclear palsy N.V. Fedorova, E.V. Bril, T.K. Kulua, A.D. Mikhaylova Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova.2021; 121(5): 111. CrossRef
Best Practices in the Clinical Management of Progressive Supranuclear Palsy and Corticobasal Syndrome: A Consensus Statement of the CurePSP Centers of Care Brent Bluett, Alexander Y. Pantelyat, Irene Litvan, Farwa Ali, Diana Apetauerova, Danny Bega, Lisa Bloom, James Bower, Adam L. Boxer, Marian L. Dale, Rohit Dhall, Antoine Duquette, Hubert H. Fernandez, Jori E. Fleisher, Murray Grossman, Michael Howell, Di Frontiers in Neurology.2021;[Epub] CrossRef
The Genetic Landscape of Parkinsonism-Related Dystonias and Atypical Parkinsonism-Related Syndromes Monica Diez-Fairen, Pilar Alvarez Jerez, Joos Berghausen, Sara Bandres-Ciga International Journal of Molecular Sciences.2021; 22(15): 8100. CrossRef
MAPT R406W increases tau T217 phosphorylation in absence of amyloid pathology Chihiro Sato, Nipun Mallipeddi, Nupur Ghoshal, Brenton A. Wright, Gregory S. Day, Albert A. Davis, Albert H. Kim, Gregory J. Zipfel, Randall J. Bateman, Audrey Gabelle, Nicolas R. Barthélemy Annals of Clinical and Translational Neurology.2021; 8(9): 1817. CrossRef
“Parkinson’s disease” on the way to progressive supranuclear palsy: a review on PSP-parkinsonism Ján Necpál, Miroslav Borsek, Bibiána Jeleňová Neurological Sciences.2021; 42(12): 4927. CrossRef
Estimation and discussion of prognosis in neurologic practice. Communication issues with patient with neurological disease E. V. Bril, A. V. Khasina, F. A. Abbasov, O. S. Zimnyakova, N. V. Fedorova Medical alphabet.2021; (22): 55. CrossRef
The Progressive Supranuclear Palsy: Past and Present Aspects Theodore P. Parthimos, Kleopatra H. Schulpis Clinical Gerontologist.2020; 43(2): 155. CrossRef
Machine Learning Techniques to Identify Dementia Nivedita Manohar Mathkunti, Shanta Rangaswamy SN Computer Science.2020;[Epub] CrossRef
My dad and progressive supranuclear palsy (PSP) Heather Angus-Leppan Practical Neurology.2020; 20(3): 263. CrossRef
Tauopathy and Movement Disorders—Unveiling the Chameleons and Mimics Jacky Ganguly, Mandar Jog Frontiers in Neurology.2020;[Epub] CrossRef
A Home-Based, Music-Cued Movement Program Is Feasible and May Improve Gait in Progressive Supranuclear Palsy Joanne E. Wittwer, Margaret Winbolt, Meg E. Morris Frontiers in Neurology.2019;[Epub] CrossRef
Association of autonomic symptoms with disease progression and survival in progressive supranuclear palsy Marcos C B Oliveira, Helen Ling, Andrew J Lees, Janice L Holton, Eduardo De Pablo-Fernandez, Thomas T Warner Journal of Neurology, Neurosurgery & Psychiatry.2019; 90(5): 555. CrossRef
Revisiting the diagnostic value of Evans’ index: lessons from an unusual case of normal pressure hydrocephalus with Evans’ index less than 0.3 Jung E. Park, Hyunjin Ju, Kayeong Im, Kyum-Yil Kwon Neurological Sciences.2019; 40(12): 2637. CrossRef
Progressive supranuclear palsy as differential diagnosis of Parkinson's disease in the elderly Ricardo Fernández-Ferreira, Raúl Anwar García-Santos, Mayela Rodríguez-Violante, Coral López-Martínez, Ivonne Karina Becerra-Laparra, María Eugenia Torres-Pérez Revista Española de Geriatría y Gerontología.2019; 54(5): 251. CrossRef
Neuroinflammation as a Common Feature of Neurodegenerative Disorders Leonardo Guzman-Martinez, Ricardo B. Maccioni, Víctor Andrade, Leonardo Patricio Navarrete, María Gabriela Pastor, Nicolas Ramos-Escobar Frontiers in Pharmacology.2019;[Epub] CrossRef
On the journey to uncover the causes of selective cellular and regional vulnerability in neurodegeneration Zane Jaunmuktane, Sebastian Brandner Acta Neuropathologica.2019; 138(5): 677. CrossRef
Clinical Milestones Preceding the Diagnosis of Multiple System Atrophy and Progressive Supranuclear Palsy: A Retrospective Cohort Study Louise Wiblin, Rory Durcan, Brook Galna, Mark Lee, David Burn Journal of Movement Disorders.2019; 12(3): 177. CrossRef
Prediction of the Clinical Severity of Progressive Supranuclear Palsy by Diffusion Tensor Imaging Yao-Liang Chen, Xiang-An Zhao, Shu-Hang Ng, Chin-Song Lu, Yu-Chun Lin, Jur-Shan Cheng, Chih-Chien Tsai, Jiun-Jie Wang Journal of Clinical Medicine.2019; 9(1): 40. CrossRef
Tauopathy with hippocampal 4‐repeat tau immunoreactive spherical inclusions: a report of three cases Gabor G. Kovacs, Linda K. Kwong, Murray Grossman, David J. Irwin, Edward B. Lee, John L. Robinson, Eunran Suh, Vivianna M. Van Deerlin, Virginia M. Lee, John Q. Trojanowski Brain Pathology.2018; 28(2): 274. CrossRef
A case of spinal anesthesia in a patient with progressive supranuclear palsy Momoka Tonan, Moritoki Egi, Nana Furushima, Satoshi Mizobuchi JA Clinical Reports.2018;[Epub] CrossRef
Is it Useful to Classify PSP and CBD as Different Disorders? Yes Helen Ling, Antonella Macerollo Movement Disorders Clinical Practice.2018; 5(2): 145. CrossRef
Difficulties in the diagnosis of four repeats (4R) tauopathic parkinsonian syndromes Piotr Alster, Ewa Krzyżanowska, Dariusz Koziorowski, Stanisław Szlufik, Dorota Różański, Joanna Noskowska, Justyna Mianowicz, Adrian Michno, Leszek Królicki, Andrzej Friedman Neurologia i Neurochirurgia Polska.2018; 52(4): 459. CrossRef
Neuro-ophthalmology of movement disorders Olga Waln, Joseph Jankovic Expert Review of Ophthalmology.2018; 13(5): 283. CrossRef
Role of Neuroimaging on Differentiation of Parkinson’s Disease and Its Related Diseases Toshihide Ogawa, Shinya Fujii, Keita Kuya, Shin-ichiro Kitao, Yuki Shinohara, Mana Ishibashi, Yoshio Tanabe Yonago Acta Medica.2018; 61(3): 145. CrossRef
Gait disorders in adults and the elderly Walter Pirker, Regina Katzenschlager Wiener klinische Wochenschrift.2017; 129(3-4): 81. CrossRef
Transcranial Magnetic Stimulation for the Assessment of Neurodegenerative Disease Steve Vucic, Matthew C. Kiernan Neurotherapeutics.2017; 14(1): 91. CrossRef
Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches Adam L Boxer, Jin-Tai Yu, Lawrence I Golbe, Irene Litvan, Anthony E Lang, Günter U Höglinger The Lancet Neurology.2017; 16(7): 552. CrossRef